Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weishuntinib tablets in previously treated unresectable recurrent or metastatic esophageal squamous cell carcinoma
CTR20243125Phase 2Active
- Sponsor
- Liushun Biotechnology
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of weishuntinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Liushun Biotechnology. Started Aug 2024; status: active.
02
Drugs
weishuntinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20243125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243125.